Patents in the Postgenomic Era: Proprietary Drug Targets and Therapies

/Home/Biologics Delivery - Protein Synthesis/Biologics Market Research - Protein Synthesis

Patents in the Postgenomic Era: Proprietary Drug Targets and Therapies
Drug and Market Development Publishing
Oct 2005
Pages: 130
Price: EUR? 5,297.00
By 2001, the United States Patent and Trademark Office (USPTO) received 34,527 biotechnology patent applications. A new report indicates patents on genes and proteins?representing potential drug targets?are quickly becoming the currency of the postgenomic era. 'Patents in the Postgenomic Era: Proprietary Drug Targets and Therapies' is the first report to attempt to assess the impact of human genome sequencing efforts on drug discovery research and to focus on the implications for the drug targets industry. The report offers information from past experiences with patenting of genes and proteins to secure potential drug targets by obtaining suitable patent protection and the results of a new survey of 9,972 postgenomic patents to assist the reader in predicting how soon products of genomics may reach advanced clinical trials.
'Patents in the Postgenomic Era: Proprietary Drug Targets and Therapies' covers general legal and regulatory requirements, as well as developments in specific areas of postgenomic drug discovery of interest to many in the industry. The report provides essential data including:
- A review of patent law and procedures to give the reader an understanding of the US system and key differences in other patent jurisdictions
- Regulatory developments relevant to patenting of genes and proteins to give the reader an appreciation of areas of controversy, potential risks and pitfalls
- The results of a new survey of 9,972 postgenomic patents to assist the reader in predicting how soon products of genomics may reach advanced clinical trials
- Analysis of postgenomic patents relating to major drug target classes to provide the reader with information on patenting ctivity in their specific area of interest
- Mining postgenomic patents for competitive intelligence to reveal to the reader the identity of the most active and the most influential patent assignees in key areas
Market Opportunities
In 2002, patents in Biotechnology, Organic Chemistry, and Pharmaceuticals grew 5.5 times as fast as patents in Physics, Optics, Systems Components, and Electrical Engineering (USPTO). The proportion of published US patents claiming novel target sequences relevant to the major drug classes rose almost three-fold in the years following 2000.
In the biomedical field, patents are extremely valuable to companies. The pharmaceutical industry has always relied on patents to safeguard the vast amount of investment required to develop and market a new drug. For biotechnology-sized businesses, they provide a means of securing investment income by establishing the company's preeminence in a particular area of technology. Patents on genes and proteins, representing potential drug targets, are the currency of the postgenomic era.
- Learn from past experiences with patenting of genes and proteins to secure potential drug targets by obtaining suitable patent protection
- Benefit from the survey of 15 years of patenting activity to develop viable drugs by choosing most promising targets and therapeutic indications
- Put patent mining theory into practice to identify potential threats and opportunities by effective use of resources and indicators of patent quality
- Build on competitive analysis of biopatents to assess your proprietary position by identifying your key competitors
Questions Answered
- How may disease-related genes and proteins be patented and which have been the most active areas of patenting?
- Which drug target classes are dominated by patents claiming novel targets?
- What 3-D protein structures have been patented within each drug target class?
- Which drug target classes are dominated by patents claiming actual therapeutics?
- Which patents claim substantial diagnostic/biomarker applications?
- Who are the most prolific and the most influential assignees of postgenomic biopatents?
- Which areas of clinical need do postgenomic patents address?